http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9915645-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ea9a1e90da665c8b18a5a50f88b5694 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1582944ab605dea4017f99ab592582ef |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-044 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92 |
| filingDate | 2014-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df3f8db466a7520584263c6b0131f4bd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d73699e8aec122c44f42961ae168cff8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ede7e472812964f72ec2696ad2ac2c7a |
| publicationDate | 2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-9915645-B2 |
| titleOfInvention | Method of treating a patient determined to be at risk of developing occult pancreatic beta-cell dysfunction |
| abstract | This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (AHB) in a single fasting baseline biological sample of the patient; (b) comparing the level of AHB in the single fasting baseline biological sample to a reference AHB level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b). An increased AHB level at fasting baseline indicates that a normoglycemic, normo-insulinemic and/or non-dyslipidemic patient has developed or has an increased likelihood of developing occult pancreatic beta cell dysfunction. An increased AHB level at fasting baseline and an elevated glucose level of at least about 155 mg/dL at 30 minutes and/or 1 hour indicates that a normoglycemic, normo-insulinemic and/or non-dyslipidemic patient has developed or has an increased likelihood of developing clinically significant post-prandial hyperglycemia. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110719272-A |
| priorityDate | 2013-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 438.